生物育種板塊拉昇 農業農村部推動農業轉基因納入政府議事日程
格隆匯1月28日丨生物育種板塊拉昇走強,豐樂種業漲超7%,隆平高科、荃銀高科漲超5%,登海種業、大北農、農發種業、神農科技等紛紛跟漲。昨日,農業農村部辦公廳印發《2021年農業轉基因生物監管工作方案》。各省級農業農村部門的年度工作目標是:積極推動農業轉基因監管納入政府議事日程,將支持農業轉基因生物安全事業發展的相關支出列入政府預算;指導從業主體辦理農業轉基因生物加工許可證,依法開展農業轉基因生物加工審批和監管等。機構指出,轉基因技術儲備豐富、轉基因性狀研發領先、品種競爭力強的龍頭公司有能力把握種業技術變革機會,依靠優質品種獲得更多市場份額。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.